close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GRAIL, Inc. - Common Stock (NQ:GRAL)

117.18 -8.46 (-6.73%)
Delayed Quote Updated: 10:37 AM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GRAIL, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Got $10,000? 3 Hot Stocks to Buy That Could Make You a Fortune ↗
Grail, Agility Robotics, and Sandisk could deliver multibagger gains in the future. 
Via The Motley Fool
News headline image
GRAIL (GRAL) Q3 2026 Earnings Call Transcript ↗
Promotional pricing lifted test volume sharply, but margins fell and losses widened. 
Via The Motley Fool
Topics Earnings
News headline image
What GRAIL (GRAL) Said on Its Q3 Earnings Call ↗
GRAIL (NASDAQ:GRAL) reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri... 
Via MarketBeat
Topics Earnings
GRAIL (NASDAQ:GRAL) Slides After Q3 Revenue Miss Despite Narrower Loss ↗
Via Chartmill
News headline image
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps ↗
Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. ↗
FDA approval will help, as will insurer adoption of Galleri, but the price that they might be willing to pay for the test is also critical. 
Via The Motley Fool
News headline image
2 Growth Stocks to Buy in October ↗
Grail and Veeva Systems could be well insulated from near-term headwinds. 
Via The Motley Fool
News headline image
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? ↗
Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets analyst projections. 
Via The Motley Fool
News headline image
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October ↗
The cancer blood test maker could have a bright future. 
Via The Motley Fool
News headline image
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run. ↗
A positive FDA vote is driving the recent surge in the multi-cancer early detection (MCED) test company. 
Via The Motley Fool
News headline image
Here's Why Grail Stock Surged 55% This Week ↗
The company received a favorable vote from the FDA this week, which could open up significant adoption of its multi-cancer early detection test, Galleri. 
Via The Motley Fool
Topics Death
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade ↗
Via Chartmill
Topics Artificial Intelligence
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 ↗
An insider sells 7,900 shares as the stock price has surged over the past year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test ↗
FDA approval for its multi-cancer early detection test, Galleri, would strengthen the case for the stock. 
Via The Motley Fool
Topics Earnings
News headline image
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting ↗
GRAIL (NASDAQ:GRAL) Chief Financial Officer Aaron Freidin said the company’s Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital... 
Via MarketBeat
News headline image
GRAIL (GRAL) Q2 2026 Earnings Call Transcript ↗
Galleri volume jumped 35% year over year on physician adoption and digital partnerships. 
Via The Motley Fool
Topics Earnings
News headline image
GRAIL Q2 Earnings Call Highlights ↗
GRAIL (NASDAQ:GRAL) reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build... 
Via MarketBeat
Topics Earnings
News headline image
Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70? ↗
The developer of blood-based cancer tests still has a bright future. 
Via The Motley Fool
News headline image
Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong. ↗
The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers. 
Via The Motley Fool
News headline image
Prediction: Grail Stock Will Skyrocket to $100 in 1 Year ↗
The cancer test maker still has a bright future. 
Via The Motley Fool
News headline image
A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors. ↗
Despite a significant setback, Grail's Galleri test still has a pathway to widespread adoption. 
Via The Motley Fool
News headline image
Why Grail Could Be the Sleeper Stock Everyone's About to Notice ↗
Grail is on a quest to win in a $50 billion market. 
Via The Motley Fool
News headline image
Here's Why Grail Stock Soared Higher in May (And Where the Company is Heading Now) ↗
Investors remain hopeful that the Galleri test can gain FDA approval and medical insurance coverage. 
Via The Motley Fool
Topics Death
News headline image
Why Grail Stock Popped Today ↗
The Galleri test failed its primary endpoint in a landmark trial, but that doesn't mean it doesn't have a big future. 
Via The Motley Fool
Topics Death
News headline image
Is Grail Stock a Bad-News Buy After Its Recent Pullback? ↗
The cancer test maker could still have a bright future. 
Via The Motley Fool
News headline image
Why Grail Shares Crashed Today ↗
The market was disappointed by the more detailed data on a landmark trial for the company's multi-cancer early detection (MCED) test. 
Via The Motley Fool
Topics Death
News headline image
GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint ↗
GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through... 
Via MarketBeat
News headline image
Grail's Slump Enters Week 10. Is There Any End in Sight? ↗
Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.